Spontaneous remission of chronic lymphocytic leucemia in a patient with SARS-CoV2. (2022)

• Record Type: Journal Article
• Authors: Bülbül, Hale; Nazlı, Hamza Ekmel; Olgun, Aybüke; Togay, Alper; Kahraman, Dudu Solakoğlu
• Is Part Of: Leukemia research reports. Volume 18(2022)
• Publication Date: 2022
• Subjects: Chronic lymphocytic leukaemia -- SARS-CoV2 -- Spontaneous remission; Leukemia -- Periodicals; Lymphomas -- Periodicals; Multiple myeloma -- Periodicals; Leukemia -- Periodicals; Lymphoma -- Periodicals; Multiple Myeloma -- Periodicals; Hematologic Neoplasms -- Periodicals; Leukemia; Lymphomas; Multiple myeloma; Electronic journals; Periodicals; 616.9941905
• DOI: 10.1016/j.lrr.2022.100336
• Languages: English
• ISSNs: 2213-0489

Abstract

Highlights: Chronic lymphocytic leukaemia (CLL) is still considered incurable. SARS-CoV2 has the ability to induce injury and death of infected cells and tissues. The main effect of SARS-CoV2 is attributed to hyperactivation of T cells. Cross-reactivity of virus-specific T cells with tumour antigens can lead to regression of tumours. Abstract: Although novel therapies have improved the treatment outcome of patients, chronic lymphocytic leukaemia (CLL) is still considered incurable. Recently, a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), causing coronavirus disease 2019 (Covid 19), emerged in late 2019, and it has posed a global health threat. In a limited number of cases, it has been shown that some lymphoma types spontaneously regress after SARS-CoV2 infection suggesting that the infection can trigger de immune system against the tumour cell. Cross-reactivity of pathogen-specific T cells with tumour antigens and natural killer cell activation can be the possible mechanism of this hypothesis.